Life Sciences BPO market seen doubling by 2035

Market Research Future projects the global life sciences business process outsourcing market will grow from $581.4 billion in 2026 to $1.2 trillion by 2035, driven by drug-price pressure, decentralized trial adoption and AI automation. CRO services remain the biggest segment, while CDMO/CMO services are the fastest-growing. Why it matters: - The life sciences BPO market is moving from cost-cutting support to a core operating layer for drug developers. - Pressure on margins, faster trial models and automation are pushing pharmaceutical and biotech companies to outsource more work. - The shift is expected to reshape clinical development, regulatory operations and manufacturing capacity through 2035. What happened: - Market Research Future said the global life sciences BPO market will rise from USD 581.4 billion in 2026 to USD 1,198.5 billion by 2035. - The forecast implies a 9.45% compound annual growth rate from 2026 through 2035. - The market base was estimated at USD 531.2 billion in 2025. - The report was released June 19, 2026. The details: - The Inflation Reduction Act’s Medicare drug-price negotiation provisions cover 60 drugs by 2029, putting more pressure on branded-drug margins. - A recent report estimates top-20 pharma companies will shift 12% to 15% of internal operational budgets toward outsourced clinical data management, regulatory affairs and commercial support by 2028. - The FDA’s May 2023 decentralized clinical trial guidance formalized remote consent, home-nursing visits and direct-to-patient drug shipment. - Sponsors using hybrid trial designs report 25% to 35% faster enrollment and 20% lower per-patient costs. - AI and natural-language-processing tools are automating 40% to 50% of clinical study report authoring. - The FDA Sentinel System processes about 900 million patient records a year, and outsourced safety vendors are tying into that data to speed signal detection. - Accenture estimates intelligent automation across outsourced functions can reduce cycle times by 30% to 40% and create about USD 18 billion in annual efficiency gains across the industry. - The worldwide biologics pipeline has expanded 64% since 2019 and included more than 8,400 active biologic candidates in early 2025. Between the lines: - The report frames outsourcing as a structural response to policy and operating pressure, not a temporary budget move. - CROs keep the largest share because they sit closest to trial execution and data management. - CDMO and CMO providers are gaining faster because biologics, cell therapy and gene therapy are harder to manufacture in-house. - The market remains fragmented, with the top five players holding an estimated 28% to 33% combined revenue share and an HHI below 600. - Consolidation has accelerated, including Novo Holdings’ USD 16.5 billion acquisition of Catalent, but the breadth of outsourced functions still leaves room for specialized vendors. - By 2030, MRFR expects more than 60% of pharmacovigilance case processing and 45% of regulatory submission assembly to be handled by AI-augmented workflows. What’s next: - CRO services remain the dominant segment, with about 46.9% revenue share in 2024. - CDMO/CMO services are projected to be the fastest-growing service line at 12.2% CAGR from 2026 to 2035. - Pharmaceutical companies held about 61.3% of end-user revenue in 2024, while biotechnology companies are the fastest-growing end-user group at 9.1% CAGR. - Full-service outsourcing led the market with about 49.7% share in 2024, while the functional service provider model is forecast to grow 10.6% annually. - North America led the market with about 44.8% share in 2024, followed by Europe at 26.3%. - Asia-Pacific is the fastest-growing region at 9.2% CAGR, while the Middle East and Africa and South America are smaller but expanding markets. - The report expects the market to split between providers using proprietary AI platforms and those still dependent on manual labor models. The bottom line: - Life sciences outsourcing is becoming more automated, more regulated and more strategic, with the biggest gains going to providers that can combine clinical, regulatory and manufacturing capabilities with AI-driven operations.